NYSEAMERICAN:CRMD - CorMedix Stock Price, Forecast & News

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

CorMedix shares reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The biotechnology company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.19 million. View CorMedix's Earnings History.

CorMedix is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for CorMedix.

2 analysts have issued 12-month price targets for CorMedix's shares. Their forecasts range from $14.00 to $48.00. On average, they expect CorMedix's share price to reach $31.00 in the next year. This suggests a possible upside of 392.1% from the stock's current price. View Analyst Price Targets for CorMedix.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.

Media headlines about CRMD stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CorMedix earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for CorMedix.

Some companies that are related to CorMedix include BELLUS Health (BLU), CEL-SCI (CVM), Cel-Sci (CVM), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Biotest (BIO), Trillium Therapeutics (TRIL), Rafael (RFL), Silence Therapeutics (SLN), ProMetic Life Sciences (PLI) and Theratechnologies (TH).

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), NovaBay Pharmaceuticals (NBY), AcelRx Pharmaceuticals (ACRX), Progenics Pharmaceuticals (PGNX), Kindred Biosciences (KIN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Opko Health (OPK).

CorMedix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.74%), Bank of New York Mellon Corp (0.33%), Steward Partners Investment Advisory LLC (0.27%), Charles Schwab Investment Management Inc. (0.23%), Renaissance Technologies LLC (0.22%) and UBS Group AG (0.12%). Company insiders that own CorMedix stock include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.

CRMD stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, AQR Capital Management LLC and Principal Financial Group Inc.. View Insider Buying and Selling for CorMedix.

CRMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, California Public Employees Retirement System, Barclays PLC, UBS Group AG, State Street Corp, Steward Partners Investment Advisory LLC, Panagora Asset Management Inc. and Bank of New York Mellon Corp. Company insiders that have bought CorMedix stock in the last two years include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRMD stock can currently be purchased for approximately $6.30.

CorMedix has a market capitalization of $161.61 million. CorMedix employs 22 workers across the globe.View Additional Information About CorMedix.

The official website for CorMedix is http://www.cormedix.com/.

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.